Literature DB >> 12974476

Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

Michael Croft1.   

Abstract

Interactions between co-stimulatory ligands and their receptors are crucial for the activation of T cells, the prevention of tolerance and the development of T-cell immunity. It is now evident that members of the immunoglobulin-like CD28-B7 co-stimulatory family cannot fully account for an effective long-lasting T-cell response or the generation of memory T cells. Several members of the tumour-necrosis factor receptor (TNFR) superfamily--OX40, 4-1BB, CD27, CD30 and HVEM (herpes-virus entry mediator)--are poised to deliver co-stimulatory signals both early and late after encounter with antigen. The roles of these molecules in initiating and sustaining the T-cell response and in promoting long-lived immunity are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12974476     DOI: 10.1038/nri1148

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  305 in total

1.  Human vascular smooth muscle cells lack essential costimulatory molecules to activate allogeneic memory T cells.

Authors:  Pei Zhang; Thomas D Manes; Jordan S Pober; George Tellides
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-06-10       Impact factor: 8.311

Review 2.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

Review 3.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

4.  Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Authors:  Sujin Lee; Robert S Mittler; Martin L Moore
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

5.  Preferential use of B7.2 and not B7.1 in priming of vaccinia virus-specific CD8 T cells.

Authors:  Shahram Salek-Ardakani; Ramon Arens; Rachel Flynn; Alessandro Sette; Stephen P Schoenberger; Michael Croft
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 6.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

7.  OX40 costimulation turns off Foxp3+ Tregs.

Authors:  Minh Diem Vu; Xiang Xiao; Wenda Gao; Nicolas Degauque; Ming Chen; Alexander Kroemer; Nigel Killeen; Naoto Ishii; Xian Chang Li
Journal:  Blood       Date:  2007-06-15       Impact factor: 22.113

8.  Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome.

Authors:  Véronique M Braud; Jérôme Biton; Etienne Becht; Samantha Knockaert; Audrey Mansuet-Lupo; Estelle Cosson; Diane Damotte; Marco Alifano; Pierre Validire; Fabienne Anjuère; Isabelle Cremer; Nicolas Girard; Dominique Gossot; Agathe Seguin-Givelet; Marie-Caroline Dieu-Nosjean; Claire Germain
Journal:  Oncoimmunology       Date:  2018-01-29       Impact factor: 8.110

9.  Novel APC-like properties of human NK cells directly regulate T cell activation.

Authors:  Jacob Hanna; Tsufit Gonen-Gross; Jonathan Fitchett; Tony Rowe; Mark Daniels; Tal I Arnon; Roi Gazit; Aviva Joseph; Karoline W Schjetne; Alexander Steinle; Angel Porgador; Dror Mevorach; Debra Goldman-Wohl; Simcha Yagel; Michael J LaBarre; Jane H Buckner; Ofer Mandelboim
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 10.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.